Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report.
- Author:
Hyun Sun WOO
1
;
Kyoung Hwa LEE
;
Phill Hoon YOON
;
Su Ji KIM
;
Inkeun PARK
;
Young Saing KIM
;
Hee Kyung AHN
;
Junshik HONG
;
Dong Bok SHIN
;
Sun Jin SYM
Author Information
- Publication Type:Case Report
- Keywords: Oxaliplatin; Colorectal neoplasms; Thrombocytopenia; Neutropenia
- MeSH: Colonic Neoplasms; Colorectal Neoplasms; Female; Gingiva; Hemorrhage; Humans; Middle Aged; Neutropenia; Platinum; Purpura; Recurrence; Thrombocytopenia*
- From:Cancer Research and Treatment 2015;47(4):949-953
- CountryRepublic of Korea
- Language:English
- Abstract: Oxaliplatin is a third-generation platinum derivative used for metastatic or advanced colorectal cancer treatment. Although myelosuppression is the most common cause of oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immune-mediated thrombocytopenia are reported. We report a case of a 57-year-old woman with colon cancer who developed gum bleeding and petechiae after oxaliplatin infusion. Laboratory tests revealed grade 4 thrombocytopenia and grade 4 neutropenia. She recovered from the thrombocytopenia and accompanying neutropenia within 4 days with no recurrence following discontinuation of oxaliplatin. Physicians need to be aware of the risk of severe acute thrombocytopenia following oxaliplatin administration.
